May 29 (Fitch) Fitch Ratings has downgraded Baxter International Inc .'s ( Baxter ) long-term Issuer Default Rating (IDR) by ..... company's short-term IDR to 'F2' from 'F1'. Baxter had approximately $10 billion in outstanding debt
Karen Andersen: Baxter ( BAX ) is a diversified health-care company ..... to think about the future of the new Baxter , as it is planning to spin off its bioscience ..... continue to have economic moats. The new Baxter sees cost advantages as it is part of
COPENHAGEN, May 20 (Reuters) - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.
COPENHAGEN, May 20 (Reuters) - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia,...
May 12 (Reuters) - Baxter International Inc said it agreed to buy two drugs to treat a rare form of blood cancer from Italian drugmaker Sigma-Tau Finanziaria SpA for $900 million, before...
May 12 (Reuters) - Baxter International Inc said it agreed to buy Italian drugmaker Sigma-Tau Finanziaria SpA's portfolio of drugs to treat rare forms of blood cancer for $900 million, before expenses.
Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/257250 Key Vendors Amcor Baxter International Bemis Cardinal Health DuPont Other Prominent Vendors 3M Company Ahlstrom Alcan Alcoa Barger Becton, Dickinson and
including Merck MRK, Actavis ACT, and Baxter BAX . Even though several years have ..... Value Uncertainty Consider Buying Baxter $84 Wide Low $67.20 Elekta SEK ..... 55.20 Data as of 3-26-15 Baxter BAX Although competition is increasing
AAPL ] joins the DJIA and AT&T [ T ] is booted out. Baxter International [ BAX ; yield 3%; fwd EV/EBITDA 10.4] is attractive ..... upcoming split into two – medical-products [to retain Baxter name] and biopharma [to be called Baxalta ]. Steakhouse
half of 2015). Pfizer is gaining specialty injectable pharmaceuticals (68% of Hospira sales), which should strengthen ..... the infusion pump market, such as Fresenius SE FMS or Baxter BAX , could be interested in taking the device segment off